Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.85 -5.1%	$1.87	$1.21 ▼ $3.81	$45.69M	0.68	257,690 shs	289,056 shs
OMED OncoMed Pharmaceuticals		$0.89	$0.55 ▼ $3.35	$34.43M	1.86	768,904 shs	1,201 shs
PYRGF PyroGenesis Canada	$0.33 +3.0%	$0.34	$0.30 ▼ $0.71	$61.70M	0.84	11,429 shs	3,021 shs
WHWK Whitehawk Therapeutics	$1.85	$0.00	$1.21 ▼ $3.81	$87.15M	0.55	162,435 shs	34,998 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	+0.52%	-2.99%	-4.41%	+24.20%	+24.20%
OMED OncoMed Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PYRGF PyroGenesis Canada	-1.51%	-5.27%	-7.65%	+0.22%	-51.63%
WHWK Whitehawk Therapeutics	-5.13%	-6.09%	+184,999,900.00%	+184,999,900.00%	+184,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.3857 of 5 stars	1.0	0.0	0.0	0.0	0.0	2.5	1.3
OMED OncoMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	0.0914 of 5 stars	0.0	2.0	0.0	0.0	0.0	1.7	0.0
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	-9.91% Downside
OMED OncoMed Pharmaceuticals	0.00	N/A	N/A	N/A
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.82	N/A	N/A	$4.29 per share	0.43
OMED OncoMed Pharmaceuticals	$44.42M	0.00	N/A	N/A	$1.25 per share	0.00
PYRGF PyroGenesis Canada	$9.14M	6.75	N/A	N/A	($0.01) per share	-32.94
WHWK Whitehawk Therapeutics	$25.98M	3.35	N/A	N/A	$2.12 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	8/5/2025 (Estimated)
OMED OncoMed Pharmaceuticals	-$8.10M	-$0.16	N/A	N/A	N/A	-18.24%	-13.14%	-7.73%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.02	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A
WHWK Whitehawk Therapeutics	-$63.69M	$0.16	11.56	∞	N/A	99.42%	-56.73%	-48.68%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
OMED OncoMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
OMED OncoMed Pharmaceuticals	N/A	5.04	5.04
PYRGF PyroGenesis Canada	N/A	0.60	0.50
WHWK Whitehawk Therapeutics	N/A	18.95	18.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
OMED OncoMed Pharmaceuticals	45.16%
PYRGF PyroGenesis Canada	0.03%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
OMED OncoMed Pharmaceuticals	20.32%
PYRGF PyroGenesis Canada	47.68%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
OMED OncoMed Pharmaceuticals	22	38.69 million	N/A	Optionable
PYRGF PyroGenesis Canada	90	187.31 million	96.34 million	No Data
WHWK Whitehawk Therapeutics	40	47.11 million	23.60 million	N/A

OMED, WHWK, PYRGF, and AADI Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMED, WHWK, PYRGF, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.85 -0.10 (-5.13%)

As of 07/17/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

OncoMed Pharmaceuticals NASDAQ:OMED

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.

PyroGenesis Canada NASDAQ:PYRGF

$0.33 +0.01 (+3.03%)

As of 10:52 AM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Whitehawk Therapeutics NASDAQ:WHWK

$1.85 0.00 (0.00%)

As of 11:56 AM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time